Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Blood (2025) 146 (Supplement 1): 6304.

https://doi.org/10.1182/blood-2025-6304

Published: 2025

Journal Articles

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Sameer Melinkeri, Rahul Bhargava, Neeraj Siddarthan, Dr Dinesh Bhurani, Jayachandran P.K., Esha Kaul, Prashant Mehta, Hari Menon, Bhausaheb Bagal, Kunal Goyal, Prakash Shekhawat, Pavan Kumar Boyella, Rakesh Boya, Ram Abhinav, Rayaz Ahmed, Anil Aribandi, Ashwin V Nair, Chandran Nair, Harish Palaparthi, Lingaraj Nayak, Pawan Singh, Priyanshi Pachauri, Rajat Bhattacharya, Rajiv Kumar, Ranjit Sahoo, Sharat Damodar, Vikram Mathews, Vasu Babu Goli, Abhishek Charan, Ajay Gupta, Amul Kapoor, Anupam Chakrapani, Ashish Bakshi, Bijay Prabhakaran Nair, Bilal Kazi, Debranjani Chattopadhyay, Ganesh S. Jaishetwar, Kaushal Kalra, Kishore Kumar, Lekshmon K.S, Madhav Danthala, Mallikarjun Kalashetty, Narendra Anukonda, Naveen Gupta, Nivedita Dhingra, Padmaja Lokireddy, Prasad Narayanan, Parathan Karunakaran, Prasanth Ganesan, Punit Jain, Priyanka Samal, Ramaswamy N.V., Rajan Kapoor, Shyam Aggarwal, Roy J Palatty, Sainath Bhethanabhotla, Sachin Almel, Santhosh Devadas, Sivakumaran Janakiraman, Sudeep V, Sreeraj Vasudevan, Sameer Tulpule, Suraj Chiraniya, Vijay Patil, Sumita Chaudhry, T Raja, Sunu Cyriac, Shishir Seth, Chezhian Subash, Varun Rajan, Alok Shetty, Vishwanath Sathyanarayanan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayashree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2025-6288

Published: 2025

Journal Articles

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access

Atharva Karulkar, Hasmukh Jain, Devanshi Kalra, Smrithi Ravikumar, Anand Vaibhaw, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Neeraj Siddarthan, Pavan Kumar Boyella, Sanket Shah, Sameer Melinkeri, Anshul Gupta, Prashant Mehta, Chandran Nair, Dinesh Bhurani, Akshay Lahoti, Anupam Chakrapani, Balakrishna Padate, Prakash Shekhawat, Priyanka Samal, Rajat Bajaj, Rumesh Chandar, Padmaja Lokireddy, Anil Aribandi, Bhausaheb Bagal, Girish Badarkhe, Jayachandran P.K., Kripa Bajaj, Nataraj KS, Nishad Dhakate, Rajan Kapoor, Rahul Bhargava, Sameer Tulpule, Sharat Damodar, Sunil Gupta, Suraj Chiraniya, Suvir Singh, Rajasekar Thirugnanam, Vasu Babu Goli, Vikram Mathews, Esha Kaul, Krishna Reddy Golamari, Kannan Subramanian, Lingaraj Nayak, Alok Shetty, Aditya Murali, Punit Jain, Rajat Bhattacharyya, Rakesh Boya, Ram Abhinav, Velu Nair, Hari Menon, Monisha Harimadhavan, Mohammed Sadique Ansari, Nishant Tiwari, Shamil Darbar, Supriya Chawkekar, Sushmita Sahay, Manivasagam Sundharam, Ashish Saroha, Moumita Basu, Anjali Jaiswal, Yuktam Yadav, Sakshi Soni, Jayshree Thorat, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Manju Sengar, Rahul Purwar

Blood (2025) 146 (Supplement 1): 1076.

https://doi.org/10.1182/blood-2025-1076

Published: 2025

Journal Articles

Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Blood (2024) 144 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2024-202335

Published: 2024

Journal Articles

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Luis A. Carvajal, Tressa Hood, Yana Bevan, Richard Dillon, Nicola Potter, Ian Thomas, Sean Johnson, Jad Othman, Amanda Gilkes, Nigel H. Russell, Adam Sikorski, Pete Ellis, Giovanni Marsico, Greg Jones, Crystal MacKenzie, Zung To, Jorge DiMartino, Pavan Kumar

Blood (2022) 140 (Supplement 1): 3377–3378.

https://doi.org/10.1182/blood-2022-159154

Published: 2022

Journal Articles

SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents

Luis A. Carvajal, Michael McKeown, Tressa Hood, Pavan Kumar, Douglas C. Saffran, Jorge DiMartino

Blood (2022) 140 (Supplement 1): 5932–5933.

https://doi.org/10.1182/blood-2022-159087

Published: 2022

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1- mutated Acute Myeloid Leukemia

John C. Byrd, Jorge E. Cortes, Mark D. Minden, Thomas Oellerich, Eytan M. Stein, Jenna Elder, Pavan Kumar, Gordon Bray, Jorge DiMartino, Wendy Stock

Blood (2021) 138 (Supplement 1): 1282.

https://doi.org/10.1182/blood-2021-145773

Published: 2021

Journal Articles

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

Melinda A. L. Day, Philipp Sergeev, Caroline A. Heckman, Anna Schinzel, Nikolaus D. Obholzer, Charles Y. Lin, Pavan Kumar, Jorge DiMartino, Douglas C. Saffran

Blood (2021) 138 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2021-146180

Published: 2021

Journal Articles

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Blood (2020) 136 (13): 1520–1534.

https://doi.org/10.1182/blood.2019002655

Published: 2020

Includes: Supplemental data

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Chandrika Gowda, MBBS, Chunhua Song, MD, Yali Ding, PhD, Pavan kumar Dhanyamraju, PhD, Soumya Iyer, PhD, Jonathon Payne, Yevgeniya Bamme, MD, Arati Sharma, PhD, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2634.

https://doi.org/10.1182/blood-2019-131790

Published: 2019

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape

Chandrika Gowda, MBBS, Chunhua Song, MD, Sadie Steffens, PhD, Yali Ding, PhD, Bo Zhang, Feng Yue, PhD, Soumya Iyer, PhD, Pavan kumar Dhanyamraju, PhD, Jonathon Payne, Morgann Reed, BS, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2522.

https://doi.org/10.1182/blood-2019-131200

Published: 2019

Journal Articles

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Shivaprasad Manjappa, MD, Mark A. Fiala, BS, Pavan Kumar Bhamidipati, MBBS, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MDMBA, Tanya M. Wildes, MDMSCI

Blood (2017) 130 (Supplement 1): 1860.

https://doi.org/10.1182/blood.V130.Suppl_1.1860.1860

Published: 2017

Journal Articles

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Ningying Wu, PhD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Camille N. Abboud, MD

Blood (2017) 130 (Supplement 1): 3204.

https://doi.org/10.1182/blood.V130.Suppl_1.3204.3204

Published: 2017

Journal Articles

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

Pavan Kumar Bhamidipati, MBBS, MD, Armin Ghobadi, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Peter Westervelt, MDPhD, Geoffrey L. Uy, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4566.

https://doi.org/10.1182/blood.V130.Suppl_1.4566.4566

Published: 2017

Journal Articles

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, Camille N. Abboud, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4567.

https://doi.org/10.1182/blood.V130.Suppl_1.4567.4567

Published: 2017

Journal Articles

Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

Dhruv Bansal, MD, Pavan Kumar Bhamidipati, MBBS, MD, Natasha Catherine Edwin, MD, Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, MD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Jingxia Liu, Rizwan Romee, MD

Blood (2016) 128 (22): 4696.

https://doi.org/10.1182/blood.V128.22.4696.4696

Published: 2016

Journal Articles

Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning

Se young Han, MD, Rizwan Romee, MD, Michael Slade, BA, Pavan Kumar Bhamidipati, MBBS, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, Yu Tao, PhD

Blood (2016) 128 (22): 3477.

https://doi.org/10.1182/blood.V128.22.3477.3477

Published: 2016

Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Ramzi Abboud, MD, Jesse Keller, MD, Michael Slade, BA, Michael P. Rettig, PhD, Stephanie Meier, John F. DiPersio, MD PhD, Todd A Fehniger, MD PhD, Kathryn Trinkaus, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MD, Camille N. Abboud, MD FACP, Khoan Vu, MD, Pavan Kumar Bhamidipati, MBBS,MD, Rizwan Romee, MD

Blood (2015) 126 (23): 3106.

https://doi.org/10.1182/blood.V126.23.3106.3106

Published: 2015

Journal Articles

Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells

Blood (2015) 126 (23): 1643.

https://doi.org/10.1182/blood.V126.23.1643.1643

Published: 2015

Journal Articles

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Vincent Ribrag, Jean-Charles Soria, Professor, Jean-Marie Michot, Anna Schmitt, MD, Sophie Postel-Vinay, MD, Fontanet Bijou, MD, Blythe Thomson, MD, Heike Keilhack, PhD, Stephen J. Blakemore, PhD, Larisa Reyderman, PhD, Pavan Kumar, PhD, Greg Fine, MS, Alice McDonald, Peter T Ho, PhD MD, Antoine Italiano, MD

Blood (2015) 126 (23): 473.

https://doi.org/10.1182/blood.V126.23.473.473

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access

Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1- mutated Acute Myeloid Leukemia

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only